title: [Treatment of MDS].
authors.forename: Kensuke
authors.initials: K
authors.lastname: Usuki
mesh_terms: D064591:Allografts; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D064592:Autografts; D001374:Azacitidine / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D017707:Erythrocyte Transfusion; D004921:Erythropoietin / Q000627:therapeutic use; D006680:HLA Antigens; D018380:Hematopoietic Stem Cell Transplantation; D006648:Histocompatibility; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D060828:Induction Chemotherapy; D007502:Iron Chelating Agents / Q000627:therapeutic use; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019172:Transplantation Conditioning / Q000379:methods
chemical_list: D020533:Angiogenesis Inhibitors; D000964:Antimetabolites, Antineoplastic; D004791:Enzyme Inhibitors; D006680:HLA Antigens; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D007502:Iron Chelating Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D013792:Thalidomide; D000077269:Lenalidomide; D001374:Azacitidine